NASDAQ: CVCapsovision Inc Stock
$7.29+0.13 (+1.82%)
Updated Mar 31, 2026
CV Price
$7.29
Fair Value Price
-$2.46
Market Cap
$363.32M
52 Week Low
$3.45
52 Week High
$15.37
P/E
-7.08x
P/B
27.4x
P/S
19.37x
PEG
N/A
Dividend Yield
N/A
Revenue
$13.55M
Earnings
-$25.32M
Gross Margin
52.9%
Operating Margin
-186.59%
Profit Margin
-186.8%
Debt to Equity
0.37
Operating Cash Flow
-$23M
Beta
1.06
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CV Overview
Medical‑technology company developing advanced capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and AI-enabled imaging platforms for gastrointestinal diagnostics
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CV's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
CV
Ranked#57 of 101
Ranked#57 of 101
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.13 | A | |
| $9.21 | A | |
| $26.13 | A |
Be the first to know about important CV news, forecast changes, insider trades & much more!
CV News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CV ($7.29) is overvalued by 396.37% relative to our estimate of its Fair Value price of -$2.46 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CV ($7.29) is not significantly undervalued (396.37%) relative to our estimate of its Fair Value price of -$2.46 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CV due diligence checks available for Premium users.
Valuation
CV fair value
Fair Value of CV stock based on Discounted Cash Flow (DCF)
Price
$7.29
Fair Value
-$2.46
Undervalued by
396.37%
CV ($7.29) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CV ($7.29) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.08x
Industry
24x
Market
30.95x
CV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
27.4x
Industry
3.27x
CV is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CV's financial health
Profit margin
Revenue
$3.9M
Net Income
-$7.4M
Profit Margin
-188.7%
CV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CV's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$18.2M
Liabilities
$4.9M
Debt to equity
0.37
CV's short-term assets ($16.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CV's short-term assets ($16.67M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.7M
Investing
-$8.0k
Financing
$15.0k
CV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CV vs Medical Device Stocks
Capsovision Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.